Aurealis Therapeutics is a clinical-stage Swiss-Finnish Biotechnology company developing bacteria-based cell and gene therapies for chronic wounds and cancer. Aurealis platform is based on safe lactic acid bacteria genetically engineered to produce multiple human therapeutic proteins and acting as millions of nanoscale bioreactors in the human body to cure multi-factorial diseases.
| Building | C |
|---|---|
| Industry | Biotech |
| Research Topics | Cell & gene therapies (chronic wounds & cancer) synthetic biology, cell and gene therapy platform |
| Employees | 2 |
| Founding year | 2018 |
Home 
About us 
Offer 
News 